GSK divests its rare disease gene therapy portfolio
April 12, 2018 at 11:48 AM EDT
The Big Pharma company is getting a 20 percent equity stake in a London gene therapy company. GSK said it plans to focus its cell and gene therapy research on new treatments for cancer.
